SCHEMBL296496

SCHEMBL296496

[CH2]Cc1cc(N(CC)CC)cc(N(CC)CC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
MAPK1 P28482 3/20 0.38
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
GFER P55789 2/20 0.38
PSMD14 O00487 1/20 0.38
RECQL P46063 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TERT O14746 1/20 0.38
S100B P04271 1/20 0.36
ALDH3A1 P30838 1/20 0.35
ALDH1A3 P47895 1/20 0.35
CNR2 P34972 1/20 0.35
MAPT P10636 4/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
TP53 P04637 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14283536 0.82 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL19960883 0.80 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL7589217 0.76 ALDH1A1 (0.54) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL297156 0.75 TSHR (0.39) ALDH1A1MAPK1CYP3A4TSHRTDP1
SCHEMBL297874 0.75 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL19960843 0.73 ALDH1A1 (0.40) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL20312800 0.72 S100B (0.45) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL19960884 0.70 S100B (0.43) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL8675403 0.70 ALDH1A1 (0.43) ALDH1A1L3MBTL1MAPK1CYP3A4TSHR
SCHEMBL297824 0.68 ALDH1A1 (0.41) ALDH1A1L3MBTL1CYP3A4TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501897-B1 METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES BASF SE (DE) 2012-03-14 EP disclosed
US-7807836-B2 Preparation of perylen-3,4:9,10-tetracarboxylic dianhydride and also of naphtalene-1,8-dicarboximides BASF AKTIENGESELLSCHAFT (DE) 2010-10-05 US disclosed
US-20080161569-A1 PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES BASF AKTIENGESELLSCHAFT (DE) 2008-07-03 US disclosed
US-7393956-B2 Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides BASF AKTIENGESELLSCHAFT (DE) 2008-07-01 US disclosed
US-20050131220-A1 Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides BASF AKTIENGESELLSCHAFT (DE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161569-A1 PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES CLIC1, PNPO, CLIC4 ALDH1A1 1464/4885L3MBTL1 4414/4885MAPK1 3238/4885
US-20050131220-A1 Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides CBR1, CBR3, SCO2 ALDH1A1 2188/4885L3MBTL1 4448/4885MAPK1 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.